Form 4: DiaMedica Therapeutics Insider Buys $3 Million in Stock

Thomas Von Koch, a director and 10% owner of DiaMedica Therapeutics, indirectly purchased 1,200,000 shares of DMAC at $2.50 per share on June 28, 2024.

Summary

• On June 28, 2024, Thomas Von Koch, a director and 10% owner of DiaMedica Therapeutics Inc. (DMAC), acquired 1,200,000 common shares at a price of $2.50 per share.
• The transaction was a purchase, increasing his indirect beneficial ownership.
• Following the transaction, Von Koch's indirect beneficial ownership totals 5,526,435 shares.
• The shares are owned directly by TomEnterprise Private AB and indirectly by Thomas Von Koch in his capacity as the board member of TomEnterprise AB.
• Thomas Von Koch has sole power to vote and dispose of these shares.

Sentiment

Score: 6

Explanation: Insider buying is generally viewed as a positive sign, suggesting confidence in the company's future. However, it's just one data point and needs to be considered alongside other factors.

Positives

• Insider buying can be seen as a positive signal, indicating that a director believes the company's stock is undervalued.

Industry Context

Insider buying is a common occurrence and is often monitored by investors as an indicator of management's confidence in the company's prospects. Large purchases, such as this one, can be particularly noteworthy.

Stakeholder Impact

• The purchase could increase investor confidence in DiaMedica Therapeutics.

Key Dates